大青龍湯與清冠一號遠距COVID-19治療與預防個案報告

台灣移居美國德州海外華僑家庭，在多方傳染源下，發生一家四口中三名家庭成員群聚感染COVID-19疫情。適時衛福部公告國內中藥緊急授權使用，台灣家人得知後接洽本醫療單位，安排遠距視訊，給予海外中醫醫療援助。歷經詳細遠距診療後，以經方治療思路，給予大青龍湯與輔助緊急授權中藥清冠一號，有效緩解SARS-COV-2病毒感染造成的呼吸道、嗅覺症狀、並預防保護了密集接觸家庭照顧者的傳染性。台灣健保與防疫成績在國際間，享有盛名，如何推動外交醫療與海外醫療，在疫病大流行期間進行中醫海外遠距醫療，值得政府有關單位借鏡參考。

關鍵字

傷寒雜病論；大青龍湯；中藥清冠一號；遠距醫療；新冠肺炎

並列摘要

Taiwanese immigrated family in Texas, USA., infected by multiple sources of SARS COV-2, three members of a family of four were confirmed as the COVID-19 community-based cluster infection came to our traditional telemedicine clinic. At the same time, Taiwan government, the Ministry of Health and Welfare, legally consented to the emergency use authorization of traditional medicine NRICM101. One cognate in Taiwan came to Taipei traditional clinic to arrange telemedicine for his oversea son and all other members. Through messenger app evaluation and diagnosis, we prescribed Daqinglong Tang and NRICM101 as the major and preventive formulars to release the respiratory system and anosmia induced by COVID-19, in all quarantine persons and healthy caregiver successfully. Taiwan's collective efforts of COVID-19 is so well-known globally in her health insurance coverage and epidemic prevention. The diplomatic medical aid and traditional medicine overseas telemedicine strategy in our model were highly valuable and worthy of official development in the global future.

並列關鍵字

Daqinglong Tang ； NRICM101 ； telemedicine ； COVID-19

參考文獻

林恭儀、黃建榮、鄭宏足、陳文戎、陳曉鈞、王翊錞、吳詩儀、盧景裕、劉姿妤：新型冠狀病毒（SARS-CoV-2）感染中醫整合臨床處置暫行指引第一版。中醫藥研究論叢；23卷2期（2020/05），181-191。doi:10.6516/TJTCM.202006/SP_23.0002

Tsai KC, Huang YC, Liaw CC, Tsai CI, Chiou CT, Lin CJ, Wei WC, Lin SJ, Tseng YH, Yeh KM, Lin YL, Jan JT, Liang JJ, Liao CC, Chiou WF, Kuo YH, Lee SM, Lee MY, Su YC. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomed Pharmacother. 2021 Jan; 133: 111037. doi: 10.1016/j.biopha.2020.111037. Epub 2020 Nov 19. PMID: 33249281; PMCID: PMC7676327.

Gudziol H, Kirschstein T, Pletz MW, Weis S, Guntinas-Lichius O, Bitter T; CoNAN study group. High prevalence of long-term olfactory dysfunction confirmed by olfactory testing after a community COVID-19 outbreak. HNO. 2021 Dec 23: 1-8. doi: 10.1007/s00106-021-01129-7. Epub ahead of print. PMID: 34940903; PMCID: PMC8697538.

An X, Zhang Y, Duan L, Jin D, Zhao S, Zhou R, Duan Y, Lian F, Tong X. The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19. Biomed Pharmacother. 2021 May; 137: 111267. doi: 10.1016/j.biopha.2021.111267. Epub 2021 Jan 14. PMID: 33508618; PMCID: PMC7836975.

Li Y, Chu F, Li P, Johnson N, Li T, Wang Y, An R, Wu D, Chen J, Su Z, Gu X, Ding X. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification. J Ethnopharmacol. 2021 May 10; 271: 113854. doi: 10.1016/j.jep.2021.113854. Epub 2021 Jan 26. PMID: 33513419; PMCID: PMC7835541.

主題瀏覽